Bard expanding presence in vascular graft market via Impra acquisition.
This article was originally published in The Gray Sheet
Executive Summary
BARD TO EXPAND VASCULAR GRAFT PRESENCE VIA IMPRA ACQUISITION by gaining the number two player worldwide in the polytetrafluoroethylene (PTFE) vascular graft market. Bard announced Aug. 5 that it has entered an agreement to acquire Tempe, Arizona-based Impra in a cash transaction "targeted for completion in the third quarter." Terms of the deal were not disclosed.